B型主动脉夹层患者胸主动脉腔内修复术后使用β受体阻滞剂与早期主动脉重塑改善相关
基于血管质量倡议数据库2012至2020年1114例因B型主动脉夹层行胸主动脉腔内修复术的患者,平均随访18±12个月,出院及随访时继续使用β受体阻滞剂者935例(84%)。调整临床和解剖因素后,术后使用β受体阻滞剂与完全假腔血栓形成增加相关(HR 1.56;95%CI 1.10-2.21;P=0.012),但未影响死亡率和主动脉相关再干预。
要点
- 术后使用β受体阻滞剂与完全假腔血栓形成增加独立相关(HR 1.56;95%CI 1.10-2.21;P=0.012)。
- 18个月时使用β受体阻滞剂者完全假腔血栓形成率58% vs 47%(log-rank P=0.018)。
- 慢性B型主动脉夹层亚组中,使用β受体阻滞剂者完全假腔血栓形成率59% vs 38%(log-rank P=0.038)。
核心结论
- 术后使用β受体阻滞剂与胸主动脉腔内修复术治疗B型主动脉夹层后完全假腔血栓形成的促进相关。
- 除急性期作用外,β受体阻滞剂抗冲动控制似乎有助于有利的主动脉重塑,并可能改善胸主动脉腔内修复术后的患者结局,尤其是慢性B型主动脉夹层患者。
研究设计与样本
- 回顾性查询血管质量倡议数据库,纳入2012至2020年因B型主动脉夹层行胸主动脉腔内修复术的全部患者,共1114例,平均随访18±12个月。
- 比较术后使用与未使用β受体阻滞剂患者的主动脉相关再干预、全因死亡及胸主动脉腔内修复术对治疗段假腔血栓形成的影响,采用Cox比例风险模型估计β受体阻滞剂治疗的效应。
主要发现
- 1114例患者平均年龄61.1±11.9岁,791例(71%)为男性;935例(84%)在出院及随访时继续使用β受体阻滞剂。
- 使用β受体阻滞剂者入口破口位于1至2区的比例更高(22% vs 13%;P=0.022)。
- 18个月时,使用β受体阻滞剂者完全假腔血栓形成显著更多(58% vs 47%;log-rank P=0.018),主动脉相关再干预率(13% vs 9%;log-rank P=0.396)和死亡率(0.2% vs 0.7%;log-rank P=0.401)相似。
- 调整临床和解剖因素后,术后使用β受体阻滞剂与完全假腔血栓形成增加相关(HR 1.56;95%CI 1.10-2.21;P=0.012),但未影响死亡率或主动脉相关再干预。
- 急性与慢性B型主动脉夹层亚组分析显示,慢性B型主动脉夹层使用β受体阻滞剂者完全假腔血栓形成率更高(59% vs 38%;log-rank P=0.038),而急性B型主动脉夹层两组间无差异(58% vs 51%;log-rank P=0.158);术后使用血管紧张素转换酶抑制剂未影响完全假腔血栓形成、死亡率和主动脉相关再干预率。
临床怎么用
- 作者认为,除急性期作用外,β受体阻滞剂抗冲动控制似乎有助于有利的主动脉重塑,并可能改善胸主动脉腔内修复术后的患者结局,尤其是慢性B型主动脉夹层患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Beta-blockers (BBs) are first-line anti-impulse therapy for patients presenting with acute type B aortic dissection (TBAD). However, little is understood about their effects after aortic repair. The aim of the present study was to evaluate the role of postoperative BB use on the outcomes of thoracic endovascular aortic repair (TEVAR) in TBAD. METHODS: The Vascular Quality Initiative database was queried for all patients who had undergone TEVAR for TBAD from 2012 to 2020. Aortic-related reintervention, all-cause mortality, and the effects of TEVAR on false lumen thrombosis of the treated aortic segment were assessed and compared between patients treated with and without BBs postoperatively. Cox proportional hazards models were used to estimate the effect of BB therapy on the outcomes. RESULTS: A total of 1114 patients who had undergone TEVAR for TBAD with a mean follow-up of 18 ± 12 months were identified. The mean age was 61.1 ± 11.9 years, and 791 (71%) were men. Of the 1114 patients, 935 (84%) continued BB therapy at discharge and follow-up. The patients taking BBs were more likely to have had an entry tear originating in zones 1 to 2 (22% vs 13%; P = .022). The prevalence of acute, elective, and symptomatic aortic dissection, prevalence of concurrent aneurysms, number of endografts used, distribution of proximal and distal zones of dissection, and operative times were comparable between the two cohorts. At 18 months, significantly more complete false lumen thrombosis (58% vs 47%; log-rank P = .018) was observed for patients taking BBs, and the rates of aortic-related reinterventions (13% vs 9%; log-rank P = .396) and mortality (0.2% vs 0.7%; log-rank P = .401) were similar for patients taking and not taking BBs, respectively. Even after adjusting for clinical and anatomic factors, postoperative BB use was associated with increased complete false lumen thrombosis (hazard ratio, 1.56; 95% confidence interval, 1.10-2.21; P = .012) but did not affect mortality or aortic-related reintervention. A secondary analysis of BB use for those with acute vs chronic TBAD showed a higher rate of complete false lumen thrombosis for patients with chronic TBAD and taking BBs (59% vs 38%; log-rank P = .038). In contrast, no difference was found in the rate of complete false lumen thrombosis for those with acute TBAD between the two cohorts (58% vs 51%; log-rank P = .158). When analyzed separately, postoperative angiotensin-converting enzyme inhibitor use did not affect the rates of complete false lumen thrombosis, mortality, and aortic-related reintervention. CONCLUSIONS: BB use was associated with promotion of complete false lumen thrombosis for patients who had undergone TEVAR for TBAD. In addition to its role in the acute setting, anti-impulse control with BBs appears to confer favorable aortic remodeling and might improve patient outcomes after TEVAR, especially for those with chronic TBAD.
引用
- Chang H, Rockman CB, Ramkhelawon B, et al. Beta-blocker use after thoracic endovascular aortic repair in patients with type B aortic dissection is associated with improved early aortic remodeling. J Vasc Surg. 2022. PMID: 35868420. doi:10.1016/j.jvs.2022.06.100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。